Commencing its business as trading pharmaceutical products, CCM stage its game to manufacturing drugs by obtaining license from the government. As there are many patents involved in manufacturing drugs, the industry find less competitors. However, emergence of strong competitors recently in the market has made the competition tougher than ever. As most of the people purchasing decisions of pharmaceutical products depend largely on the effectiveness rather than pricing, it won't be a problem for CCM to adjust their price. In terms of branding, the company has few well established products such as Thompson cough reliever and Chewes kids' vitamin which gain the loyalty of its customers' base. Based on its cash flow statements for the past ten years, there are no acquisitions of any subsidiary nor associates where the company generates its growth mostly internally which are different from other pharmaceutical company's expansion strategy.

As the company ventures itself into an industry that adapts automation process, recent rise of utility rate will hugely affect the company's margin unless the company adjusts its price. 

Based on the graph, the company has been performing on a gradual upward trend for the past ten years. Although there is a sharp decrease during 2011, it quickly recovered to the level before 2010. Both ratios are up to expectations as the company has been performing efficiently. From what I see, the company is adapting a very conservative strategy where the growth is steady and minimal risks are bared. Overall, the company performs well and possesses the potential to grow steadily in the future.